Amir Heshmatpour Buys 3,000 Shares of Neonc Technologies (NASDAQ:NTHI) Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Amir Heshmatpour bought 3,000 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were acquired at an average cost of $4.37 per share, with a total value of $13,110.00. Following the transaction, the chief executive officer owned 3,087,000 shares in the company, valued at approximately $13,490,190. This represents a 0.10% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Neonc Technologies Stock Performance

NASDAQ NTHI opened at $5.53 on Wednesday. Neonc Technologies Holdings, Inc. has a one year low of $3.01 and a one year high of $12.99. The company’s 50 day moving average price is $4.14 and its 200 day moving average price is $6.02.

Neonc Technologies (NASDAQ:NTHI) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.46).

Neonc Technologies News Summary

Here are the key news stories impacting Neonc Technologies this week:

• Positive Sentiment: NEO100 reached a Phase 2a endpoint: The company reported that NEO100 produced positive Phase 2a results in recurrent IDH1-mutant high-grade glioma, including extended survival. The update strengthens the investment case for NeOnc’s central-nervous-system drug platform and could support further development or partnership interest. Neonc NEO100 Hits Phase II Endpoint, Extends Survival in Recurrent Glioma
• Positive Sentiment: Repeated CEO insider buying is supporting sentiment: Heshmatpour purchased 12,000 shares on August 14 for approximately $45,480, 3,000 shares on August 17 for $13,110, and another 9,000 shares on August 18 for $49,860. The purchases increased his already substantial ownership and signal management confidence, although insider buying does not guarantee clinical or financial success. SEC Form 4 Filing
• Neutral Sentiment: Analyst views remain mixed: Several firms maintain Buy ratings and price targets ranging from $13 to $20, while other services have issued Hold or Sell opinions. The reported consensus rating is Hold, highlighting both the substantial upside analysts see and the risks surrounding this early-stage biotech.
• Neutral Sentiment: Shareholder actions expand financing capacity: Stockholders elected directors and approved an expansion of the equity plan by 1 million shares. The authorization may provide capital for development, but it also creates potential future dilution for existing shareholders. NeOnc Stockholders Elect Directors, Approve Equity Plan Expansion
• Negative Sentiment: Recent earnings results were weak: NeOnc reported a quarterly loss of $0.58 per share, significantly wider than the $0.12 loss analysts expected. The miss underscores the company’s ongoing cash-burn and execution risks while its clinical programs remain in development.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on NTHI shares. Maxim Group initiated coverage on shares of Neonc Technologies in a research report on Monday, May 18th. They set a “buy” rating and a $20.00 price target for the company. BTIG Research restated a “buy” rating and set a $15.00 price objective on shares of Neonc Technologies in a research note on Tuesday, May 26th. Alliance Global Partners started coverage on Neonc Technologies in a research report on Tuesday, May 19th. They issued a “buy” rating and a $13.00 target price for the company. Wall Street Zen lowered Neonc Technologies from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Weiss Ratings lowered Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, June 24th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Neonc Technologies currently has an average rating of “Hold” and an average price target of $16.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Barclays PLC grew its holdings in Neonc Technologies by 5,314.8% during the 4th quarter. Barclays PLC now owns 9,151 shares of the company’s stock valued at $76,000 after purchasing an additional 8,982 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in Neonc Technologies in the 4th quarter worth $124,000. OMERS ADMINISTRATION Corp purchased a new position in Neonc Technologies in the 4th quarter valued at about $126,000. Global Retirement Partners LLC purchased a new position in Neonc Technologies in the 2nd quarter valued at about $126,000. Finally, Royal Bank of Canada purchased a new position in Neonc Technologies in the 1st quarter valued at about $247,000.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.